Home Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy
Article Open Access

Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy

  • Fang-Zhou Xu , Fu-Rong Meng , Wan-Jing Li , Lu Xu , Hao Zhang , Yan-Bei Zhang and Xiao-Yun Fan EMAIL logo
Published/Copyright: July 24, 2024

Abstract

The aim of this study is to assess the impact of serum magnesium (Mg) levels on prognostic outcomes in patients with non-small cell lung cancer (NSCLC) undergoing treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). A cohort comprising 91 patients with NSCLC with epidermal growth factor receptor mutations received EGFR-TKI therapy. Assessments of liver and kidney function and electrolyte levels were conducted before treatment initiation and after completing two cycles of EGFR-TKI therapy. Data on variables such as age, gender, presence of distant metastasis, smoking history, other therapeutic interventions, and the specific TKI used were collected for analysis. Cox regression analysis revealed that patients with higher Mg levels prior to EGFR-TKI therapy had significantly longer progression-free survival (PFS) and overall survival (OS). Elevated Mg levels remained predictive of PFS and OS after two cycles of EGFR-TKI therapy. Multiple regression analysis confirmed these findings. Additionally, it was observed that smokers might represent a unique population, demonstrating a correlation between OS and Mg levels. Our findings indicate that serum Mg level is a prognostic factor in patients with NSCLC undergoing EGFR-TKI therapy. This may provide new insights into the underlying mechanisms of EGFR-TKI therapy related to electrolyte balance.

1 Introduction

Non-small-cell lung cancer (NSCLC) originates in the epithelial cells lining the pulmonary airways and includes distinct histological subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC is the most prevalent form of lung cancer, significantly contributing to cancer-associated morbidity and mortality. The introduction of targeted therapeutic interventions and lifestyle modifications has reduced the impact of lung cancer on human health [1]. Targeted and immunotherapy-based treatments have notably improved survival rates for patients with NSCLC [2]. Since 1991, reports from the American Cancer Society and Cancer Statistics Center have shown a steady decline in the cancer mortality rate, with lung cancer experiencing the most pronounced decline among the four leading cancers between 2014 and 2018 [3].

Despite the effectiveness of targeted therapy for NSCLC, drug resistance remains a significant challenge. Throughout the treatment course with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), a substantial proportion of patients experience disease progression due to inadequate therapeutic responses against the T790M mutation and other acquired resistance mechanisms [4]. The expanding array of targeted pharmacotherapeutic agents approved for clinical use has significantly enhanced the management of patients with NSCLC with metastatic EGFR mutations, particularly those harboring the acquired EGFR T790M mutation, who show progression despite ongoing EGFR-TKI treatment [4,5]. Early detection of disease progression and information about drug resistance are crucial for timely drug adjustments and essential for prolonging patient survival and enhancing the quality of life.

The strong association between magnesium (Mg) levels and the severity of various chronic diseases, some of which occur as comorbidities, underscores the importance of Mg levels as a critical observational marker. Reduced serum Mg concentrations have been linked to elevated risks of prediabetes and diabetes [6]. Lötscher et al. demonstrated that Mg enhances T cell immunity and that low serum Mg concentrations are associated with poorer outcomes in cancer immunotherapy, including chimeric antigen receptor T cell therapy [7]. Frequent hypomagnesemia is a significant predictor of decreased survival in patients with head and neck cancer undergoing chemoradiotherapy [8]. However, the relationship between hypomagnesemia and the prognosis of EGFR-TKI therapy for NSCLC has been infrequently studied. We hypothesize that Mg levels correlate with prognosis following EGFR-TKI therapy.

2 Method

2.1 Patient enrollment

From March 2016 to October 2021, 91 patients with NSCLC and EGFR mutations received EGFR-TKI therapy at the First Affiliated Hospital of Anhui Medical University. The inclusion criteria for this study were as follows: (i) a confirmed diagnosis of NSCLC with a clear pathological type; (ii) next-generation sequencing to identify specific genetic mutations; and (iii) completion of more than two cycles of oral EGFR-TKI therapy, with the first effective evaluation conducted after 60 days of treatment. The exclusion criteria were as follows: (i) patients with histologically mixed small cell carcinoma or small cell carcinoma; (ii) patients who were lost to follow-up or deceased within two months of treatment initiation; and (iii) patients with an active infection or kidney disease, as these conditions could affect hematology laboratory marker values.

  1. Informed consent: Informed consent has been obtained from all individuals included in this study.

  2. Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance with the tenets of the Helsinki Declaration, and has been approved by the Ethics Committee of The First Affiliated Hospital of Anhui Medical University (No.Quick-PJ 2023-12-60).

2.2 Data statistics

Overall survival (OS) was the primary endpoint, while progression-free survival (PFS) was the secondary endpoint. OS was measured from the initiation of EGFR-TKI therapy until all-cause mortality or the date of the last follow-up. PFS was defined as the period from the initiation of TKI therapy to disease progression, tumor metastasis, or all-cause death. Evaluations were conducted monthly during the initial two months following the commencement of EGFR TKI therapy, and subsequently, at three-month intervals. Comprehensive assessments were promptly conducted upon the exacerbation or emergence of new symptoms. The amalgamation of clinical data with findings from chest computed tomography (CT) scans was utilized to appraise therapeutic efficacy, in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).

Variables extracted included age, gender, distant metastasis, smoking history, body mass index (BMI), other treatments (thoracic surgery, chemotherapy, radiofrequency ablation, and radiotherapy), concomitant diseases (stroke, arterial hypertension, diabetes, and cardiopathy), and the choice of TKI. Non-smokers were defined as patients who had never smoked, while smokers were defined as those who had a history of smoking or had not quit smoking at the time of their cancer diagnosis. Additionally, liver and kidney function, as well as electrolyte levels (including Mg, calcium (Ca), phosphorus (P), potassium (K), blood urea nitrogen (BUN), serum creatinine (SCr), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)), was evaluated prior to and after two cycles of TKI treatment.

2.3 Statistical analyses

Continuous variables are expressed as means ± standard deviations. Univariate prognostic variables were screened using Cox regression analysis. The relationship between Mg levels and PFS and OS before and after therapy was evaluated using a multiple logistic regression model with adjustments for confounding factors. Hazard ratios (HR) are reported as relative risks with corresponding 95% confidence intervals (CI) and were derived using Cox regression analysis. Survival curves were plotted using the Kaplan–Meier method and log-rank test. The optimal cutoff Mg level was determined using the surv_cutpoint algorithm of the survival R package [9,10]. Finally, interactions between the Mg level and the other variables were examined. Statistical significance was set at P < 0.05. Statistical analyses were conducted using Empower® (www.empowerstats.com; X&Y Solutions, Inc., Boston, MA, USA), R (http://www.R-project.org), and R software (version 4.2.0) [11].

3 Results

3.1 Patient demographics

This study included 91 NSCLC patients who underwent EGFR-TKI therapy. Comprehensive patient demographic data are presented in Table 1. The median age of the patients was 61.57 years, and 52.75% were male. Among the cohort, 44 patients (48.35%) received chemotherapy prior to oral TKI treatment. Additionally, six patients (6.59%) underwent radiofrequency ablation, two patients (2.20%) underwent thoracotomy, and three patients (3.30%) underwent radiotherapy. Gefitinib was the most frequently prescribed EGFR-TKI, followed by icotinib and erlotinib. Thirty-one patients were diagnosed with arterial hypertension, 22 with diabetes, seven had a history of stroke, and four had a history of coronary heart disease.

Table 1

Demographics characteristics of 91 patients with NSCLC

Characteristics Mean ± SD Characteristics Mean ± SD
Age 61.57 ± 10.64 Coronary heart disease
ALT(U/L) 38.19 ± 156.69 No 87 (95.60%)
AST(U/L) 28.21 ± 75.12 Yes 4 (4.40%)
BUN (mmol/L) 5.27 ± 2.34 Stroke  
SCr (μmol/L) 66.65 ± 14.69 No 84 (92.31%)
K (mmol/L) 4.00 ± 0.35 Yes 7 (7.69%)
Ca (mmol/L) 2.26 ± 0.13 Chemotherapy
P (mmol/L) 1.12 ± 0.19 No 47 (51.65%)
Mg (mmol/L) 0.88 ± 0.07 Yes 44 (48.35%)
BMI 22.4 ± 3.4 Radiofrequency ablation  
Gender   No 85 (93.41%)
Female 43 (47.25%) Yes 6 (6.59%)
Male 48 (52.75%) Radiotherapy
Metastasis No 88 (96.70%)
No 7 (7.69%) Yes 3 (3.30%)
Yes 84 (92.31%) Operation  
Smoke   No 89 (97.80%)
No 66 (72.53%) Yes 2 (2.20%)
Yes 25 (27.47%) Drug
Hypertension Gefitinib 42 (46.15%)
No 60 (65.93%) Anlotinib 3 (3.30%)
Yes 31 (34.07%) Icotinib 27 (29.67%)
Diabetes   Erlotinib 9 (9.89%)
No 69 (75.82%) Osimertinib 5 (5.49%)
Yes 22 (24.18%) Afatinib 4 (4.40%)
Dacomitinib 1 (1.10%)

ALT, glutamic pyruvic transaminase; AST, glutamic oxaloacetic transaminase; BUN, blood urea nitrogen; SCr, serum creatinine; Ca, calcium; Mg, magnesium; P, phosphorus; K, potassium; BMI, body mass index.

3.2 Prognostic factors before EGFR-TKI therapy

The results of the univariate analysis of liver function, renal function, electrolytes, and medical history prior to therapy are displayed in Table 2. Cox regression analysis revealed that age and gender had little influence on OS and PFS. Renal function and other common electrolytes, such as K, P, and Ca, also had negligible effects on prognosis. ALT and AST had a negligible impact on PFS but had a protective effect on OS. Hypertension, diabetes, history of cardiovascular and cerebrovascular diseases, and history of smoking were risk factors for prognosis after EGFR-TKI therapy, though this trend was not statistically significant. Patients with higher Mg levels before EGFR-TKI therapy had significantly higher PFS and OS (P = 0.0100 and P = 0.0092, respectively). Multiple regression analysis using the Cox survival model confirmed this result (Table 3). After adjusting for variables such as gender, age, SCr, BUN, ALT, AST, disease history, and other treatments, the predictive effect on PFS and OS remained significant (HR = 0.02; 95% CI = 0.00–0.05; P = 0.0216; HR = 0.00; 95% CI = 0.00–0.06; P = 0.0017).

Table 2

Prognostic factors before EGFR-TKI treatment

Statistics PFS HR (95% CI) P value OS HR (95% CI) P value
Gender
Female 43 (47.25%) 1 1
Male 48 (52.75%) 0.85 (0.54, 1.32) 0.4617 0.64 (0.35, 1.18) 0.1519
Age 61.57 ± 10.64 0.99 (0.97, 1.01) 0.2870 1.02 (1.00, 1.05) 0.1032
Metastasis
No 7 (7.69%) 1 1
Yes 84 (92.31%) 1.50 (0.61, 3.74) 0.3784 1.06 (0.33, 3.45) 0.9177
ALT(U/L) 28.21 ± 75.12 1.00 (1.00, 1.00) 0.5770 0.96 (0.92, 1.00) 0.0829
AST(U/L) 38.19 ± 156.69 1.00 (1.00, 1.00) 0.6007 0.98 (0.95, 1.00) 0.0779
BUN (mmol/L) 5.27 ± 2.34 1.03 (0.93, 1.15) 0.5183 1.06 (0.92, 1.22) 0.4023
SCr (μmol/L) 66.65 ± 14.69 1.00 (0.98, 1.02) 0.8521 1.01 (0.99, 1.03) 0.4963
K (mmol/L) 4.00 ± 0.35 1.09 (0.58, 2.06) 0.7841 1.14 (0.45, 2.87) 0.7774
Ca (mmol/L) 2.26 ± 0.13 0.56 (0.09, 3.33) 0.5232 0.39 (0.04, 3.80) 0.4177
P (mmol/L) 1.12 ± 0.19 0.83 (0.25, 2.75) 0.7608 0.77 (0.16, 3.79) 0.7520
Mg (mmol/L) 0.88 ± 0.07 0.02 (0.00, 0.37) 0.0100 0.00 (0.00, 0.26) 0.0092
BMI 22.4 ± 3.4 1.04 (0.97, 1.11) 0.2355 1.03 (0.94, 1.13) 0.5683
Smoke
No 66 (72.53%) 1 1
Yes 25 (27.47%) 1.20 (0.73, 1.97) 0.4786 1.44 (0.75, 2.77) 0.2751
Diseases history
No 55 (60.44%) 1 1
Yes 36 (39.56%) 1.11 (0.70, 1.74) 0.6645 1.10 (0.60, 2.04) 0.7564
Other treatment
No 43 (47.25%) 1 1
Yes 48 (52.75%) 1.05 (0.66, 1.65) 0.8504 0.63 (0.34, 1.18) 0.1474
Table 3

Multiple regression equation of magnesium before EGFR-TKI treatment

Adjust I Adjust II
PFS 0.02 (0.00, 0.51) 0.0179 0.02 (0.00, 0.55) 0.0216
OS 0.00 (0.00, 0.08) 0.0023 0.00 (0.00, 0.06) 0.0017

Adjust I model – adjust for gender and age.

Adjust II model – adjust for gender, age, SCR, BUN, ALT, AST, diseases history, and other treatment.

3.3 Survival curves before EGFR-TKI therapy

Using the surv_cutpoint function in the survival R package, we determined the optimal cutoff Mg level for OS, which was 0.87 mmol/L based on the 91 patients in the study cohort. Consequently, the patients were divided into the high and low Mg level groups, comprising 55 (60.44%) and 36 (39.56%) patients, respectively. The median PFS in the high Mg group was 369 days (range: 323–478 days) compared to that of 275 days (range: 223–363 days) in the low Mg group. The survival curve analysis showed that PFS was significantly higher in the high Mg group than in the low Mg group (P = 0.023; Figure 1). Similarly, OS was higher in the high Mg group (mean: 1,026 days; range: 825–NA days) compared to that in the low Mg group (mean: 517 days; range: 450–846 days). Moreover, the difference in OS between the high Mg and low Mg groups was highly statistically significant (P = 0.00089).

Figure 1 
                  Survival curves before EGFR-TKI therapy according to Mg level: (a) PFS before EGFR-TKI treatment; (b) OS before EGFR-TKI treatment.
Figure 1

Survival curves before EGFR-TKI therapy according to Mg level: (a) PFS before EGFR-TKI treatment; (b) OS before EGFR-TKI treatment.

3.4 Prognostic factors after two EGFR-TKI treatment cycles

Given the excellent pre-treatment data, we further evaluated changes in liver and kidney function, electrolytes, and other parameters after two treatment cycles (Table 4). A univariate analysis of liver function, renal function, and electrolytes post-treatment revealed that most data indicating a decreased risk of disease progression was related to electrolyte levels, particularly Ca and Mg. Notably, only Mg remained statistically significant in terms of PFS, with an HR of 0.01 (95% CI: 0.00–0.07; P = 0.0001), whereas the P value associated with calcium was greater than 0.05, indicating a lack of statistical significance.

Table 4

Prognostic factors after two cycles of EGFR-TKI treatment

Statistics PFS HR (95% CI) P value OS HR (95% CI) P value
Gender
Female 43 (47.25%) 1 1
Man 48 (52.75%) 0.85 (0.54, 1.32) 0.4617 0.64 (0.35, 1.18) 0.1519
Age 61.57 ± 10.64 0.99 (0.97, 1.01) 0.2870 1.02 (1.00, 1.05) 0.1032
Metastasis
No 7 (7.69%) 1 1
Yes 84 (92.31%) 1.50 (0.61, 3.74) 0.3784 1.06 (0.33, 3.45) 0.9177
ALT(U/L) 30.04 ± 20.20 1.00 (0.99, 1.01) 0.5812 1.00 (0.98, 1.01) 0.5103
AST(U/L) 27.27 ± 14.01 1.01 (1.00, 1.03) 0.1704 1.01 (0.98, 1.03) 0.6172
BUN (mmol/L) 5.37 ± 1.82 1.00 (0.88, 1.14) 0.9470 1.07 (0.89, 1.27) 0.4864
SCr (μmol/L) 71.18 ± 19.67 1.00 (0.98, 1.01) 0.7131 1.00 (0.98, 1.02) 0.9446
K (mmol/L) 4.05 ± 0.67 0.94 (0.68, 1.30) 0.7101 0.88 (0.51, 1.52) 0.6437
Ca (mmol/L) 2.22 ± 0.13 0.17 (0.03, 1.09) 0.0618 0.01 (0.00, 0.22) 0.0023
P (mmol/L) 1.12 ± 0.20 1.31 (0.42, 4.13) 0.6428 0.79 (0.17, 3.70) 0.7696
Mg (mmol/L) 0.86 ± 0.09 0.01 (0.00, 0.07) 0.0001 0.01 (0.00, 0.42) 0.0154
BMI 22.4 ± 3.4 1.02 (0.96, 1.09) 0.4576 1.00 (0.98, 1.01) 0.5103
Smoke
No 66 (72.53%) 1 1
Yes 25 (27.47%) 1.20 (0.73, 1.97) 0.4786 1.44 (0.75, 2.77) 0.2751
Diseases history
No 55 (60.44%) 1 1
Yes 36 (39.56%) 1.11 (0.70, 1.74) 0.6645 1.10 (0.60, 2.04) 0.7564
Other treatment
No 43 (47.25%) 1 1
Yes 48 (52.75%) 1.05 (0.66, 1.65) 0.8504 0.63 (0.34, 1.18) 0.1474

For OS, changes in electrolyte levels were the most significant, with Mg and Ca being statistically significant factors. High Ca levels were protective for prognosis (HR = 0.01; 95% CI: 0.00–0.22; P = 0.0023). Since Ca values were only significant for OS after therapy, no additional research was conducted on this parameter. Multiple regression analysis using the Cox survival model (Table 5) adjusted for variables such as gender, age, SCr, BUN, ALT, AST, disease history, and other treatments. Changes in Mg levels continued to exhibit a predictive effect on both PFS (HR = 0.00; 95% CI: 0.00–0.06; P < 0.0001) and OS (HR = 0.00; 95% CI: 0.00–0.20; P = 0.0056).

Table 5

Multiple regression equation of Mg after two cycles of EGFR-TKI treatment

Adjust I Adjust II
PFS 0.01 (0.00, 0.09) 0.0002 0.00 (0.00, 0.06) < 0.0001
OS 0.01 (0.00, 0.25) 0.0073 0.00 (0.00, 0.20) 0.0056

Adjust I model: adjust for – gender; age.

Adjust II model: adjust for – gender; age, SCr, BUN, ALT, AST, diseases history and other treatment.

3.5 Survival curves after EGFR-TKI therapy

The surv_cutpoint function within the survival R package was used again to determine the optimal Mg cutoff value for OS, which was 0.73 mmol/L. There were 81 patients (89.01%) in the high Mg group and 10 patients (10.99%) in the low Mg group. The median PFS for patients in the high Mg group was 363 (range: 289–427) days, which was significantly higher than the 204 (range: 136–360) days for patients in the low Mg group. The survival curve revealed that the PFS was significantly prolonged in the high Mg group (P = 0.0012). The survival curve for OS produced identical results. The median survival time in the high Mg group (876 days; range: 734–NA days) was higher than that in the low Mg group (346 days; range: 225–876 days). There were significant differences between groups in terms of OS (P = 0.00091; Figure 2). The survival R package was used to determine the optimal Mg cutoff levels after therapy. These cutoff levels for serum Mg were lower than the normal range. Therefore, we divided the patients into low (group 1) and high (group 4) groups based on their Mg levels (8–10). The Mg levels were lowest in group 1. The univariate Cox regression analysis was repeated, and related variables were adjusted. The results showed that group 1 was significantly different from the other three groups (Table 6). These outcomes suggest that patients with low Mg levels following TKI therapy have a considerably poorer prognosis compared to other patients.

Figure 2 
                  Survival curves after two cycles of EGFR-TKI therapy according to Mg level: (a) PFS before EGFR-TKI therapy; (b) OS before EGFR-TKI therapy.
Figure 2

Survival curves after two cycles of EGFR-TKI therapy according to Mg level: (a) PFS before EGFR-TKI therapy; (b) OS before EGFR-TKI therapy.

Table 6

Association of serum Mg and prognosis by quartiles of serum Mg

Mg(mmol/L) PFS OS
Groups Statistics model I HR (95% CI) P value model II HR (95% CI) P value model I HR (95% CI) P value model II HR (95% CI) P value
Group4 (0.94) 25 (27.47%) 1 1 1 1
Group3 (0.86–0.94) 21 (23.08%) 1.57 (0.80, 3.06) 0.1895 1.69 (0.84, 3.40) 0.1414 1.38 (0.54, 3.53) 0.4992 1.36 (0.50, 3.68) 0.5487
Group2 (0.79–0.86) 25 (27.47%) 1.49 (0.77, 2.89) 0.2390 1.87 (0.93, 3.76) 0.0796 1.16 (0.44, 3.04) 0.7630 1.38 (0.51, 3.72) 0.5294
Group1 (−0.79) 20 (21.98%) 2.95 (1.53, 5.67) 0.0012 3.51 (1.75, 7.03) 0.0004 2.84 (1.22, 6.62) 0.0154 3.25 (1.34, 7.91) 0.0094

Adjust I model: adjust for gender and age.

Adjust II model: adjust for gender, age, SCr, BUN, ALT, AST, diseases history, and other treatment.

3.6 Interaction test

We further investigated the interactions to elucidate the relationship between Mg levels and the prognosis of EGFR-TKI therapy. Table 7 displays the interactions between Mg levels prior to TKI therapy and other variables. The interaction test results for Mg levels post-EGFR-TKI therapy are shown in Table 8. No variables for PFS interacted significantly with Mg levels either before or after therapy. However, significant variables were identified for OS.

Table 7

Interactions between Mg levels before EGFR-TKI treatment and other factors

Variables PFS OS
N HR 95%CI Low 95%CI High P value P (interaction) N HR 95%CI Low 95%CI High P value P (interaction)
Gender           0.3363           0.0080**
Female 43 0.0013 0.0000 0.4606 0.0265* 43 0.0000 0.0000 0.0008 0.0001***
Man 48 0.0411 0.0009 1.9443 0.1048   48 0.1667 0.0006 48.4894 0.5360  
Age 0.0838 0.0700
<65 56 0.1049 0.0015 7.1149 0.2946   56 0.0235 0.0001 5.6129 0.1794  
≥65 35 0.0003 0.0000 0.0595 0.0028** 35 0.0000 0.0000 0.0093 0.0015**
Diseases history       0.1132       0.0527
No 55 0.0790 0.0014 4.3862 0.2155 55 0.0453 0.0002 8.5738 0.2474
Yes 36 0.0003 0.0000 0.0739 0.0037** 36 0.0000 0.0000 0.0091 0.0016 **
Smoke 0.9610 0.0173*
No 66 0.0168 0.0005 0.6157 0.0262* 66 0.0621 0.0004 9.4641 0.2785  
Yes 25 0.0139 0.0000 11.7887 0.2139 25 0.0000 0.0000 0.0018 0.0006***
Other treatment       0.4047       0.6347
No 43 0.0019 0.0000 0.5581 0.0307* 43 0.0003 0.0000 0.7868 0.0434*
Yes 48 0.0361 0.0006 2.0195 0.1057   48 0.0030 0.0000 0.5353 0.0281*
BMI 0.8110 0.5213
Low 45 0.0274 0.0001 5.0882 0.1771   45 0.0007 0.0000 1.4918 0.0631  
High 46 0.0122 0.0002 0.6465 0.0296* 46 0.0130 0.0001 1.6263 0.0779  

*P < 0.05, **P < 0.01, and ***P < 0.001.

Table 8

Interactions between Mg levels after TKI treatment and other factors

Variables PFS OS
N HR 95% CI Low 95% CI High P value P (interaction) N HR 95%CI Low 95%CI High P value P (interaction)
Gender 0.5738 0.1012
Female 43 0.0019 0.0000 0.1430 0.0045** 43 0.0006 0.0000 0.1345 0.0074**
Man 48 0.0092 0.0003 0.3022 0.0085** 48 0.3237 0.0016 64.8369 0.6766
Age           0.2887           0.1043
<65 56 0.0160 0.0005 0.5472 0.0218* 56 0.1183 0.0008 17.5948 0.4030
≥65 35 0.0010 0.0000 0.0478 0.0005*** 35 0.0004 0.0000 0.0469 0.0014**
Diseases history 0.2900 0.0672
No 55 0.0160 0.0005 0.5584 0.0225* 55 0.1503 0.0013 17.2631 0.4336  
Yes 36 0.0009 0.0000 0.0487 0.0006*** 36 0.0001 0.0000 0.0449 0.0026** 36
Smoke           0.6774           0.0183*
No 66 0.0033 0.0001 0.0737 0.0003*** 66 0.1332 0.0019 9.3364 0.3525
Yes 25 0.0133 0.0000 4.6354 0.1481   25 0.0000 0.0000 0.0084 0.0020**
Other treatment 0.4456 0.7159
No 43 0.0013 0.0000 0.0739 0.0012** 43 0.0138 0.0001 2.5967 0.1089  
Yes 48 0.0106 0.0003 0.3967 0.0139* 48 0.0035 0.0000 0.6815 0.0355*
BMI           0.6905           0.0990
Low 45 0.0029 0.0001 0.1464 0.0035 ** 45 0.0002 0.0000 0.0766 0.0046**
High 46 0.0086 0.0002 0.3369 0.0110* 46 0.1261 0.0012 13.1979 0.3828  

* P < 0.05, **P < 0.01, and ***P < 0.001.

For pre-treatment Mg levels, the interaction test revealed that, compared to non-smokers, the Mg levels of smokers were more strongly associated with OS as a protective factor (HR < 0.0001 vs HR = 0.0621; P = 0.0173). Similarly, Mg levels were more strongly correlated with the outcomes of oral EGFR-TKI therapy in women than in men (HR < 0.0001 vs HR = 0.1667; P = 0.008).

Post-therapy, Mg levels demonstrated a specific predictive effect for OS only in smokers (HR < 0.0001 vs HR = 0.1332; P = 0.0183), but not for gender. Although there was no statistically significant difference in OS between females and males (HR = 0.0006 vs HR = 0.3237; P = 0.1012), women exhibited unique characteristics.

4 Discussion

The majority of patients eventually develop resistance to EGFR-TKI drugs, leading to disease progression. Consequently, most patients require regular evaluations using CT and nuclear imaging. However, the limitations of imaging techniques in capturing cellular metabolism hinder the timely detection of disease progression and the modification of treatment plans. Therefore, exploring the relationship between tumor-specific or other relevant blood markers and prognosis following EGFR-TKI therapy is rational [12,13].

Compared to other studies, in our study, we examined the data after two treatment cycles. Based on the results, we propose that patients with extremely low Mg levels following TKI therapy have a significantly poorer prognosis compared to other patients. Furthermore, the interaction test revealed that reduced Mg levels are more likely to be a risk factor in patients with a history of smoking. This observation aligns with previous research, which identified hypomagnesemia as a prognostic indicator of unfavorable outcomes in chemoradiotherapy for head and neck cancer [8]. Similarly, clinical studies suggest that depleted Mg levels constitute a risk factor for hepatocellular carcinoma among patients with nonalcoholic fatty liver disease [14].

Mg, an abundant bivalent cation in the human body, is primarily stored in skeletal muscle, soft tissue, and bone. Hormones or drugs rarely directly affect Mg levels, which are primarily regulated by intestinal absorption and renal excretion [15]. Mg is absorbed through two channel proteins: transient receptor potential melastatin (TRPM) channel types 6 and 7. TRPM7 is widespread, whereas TRPM6 is the primary absorption channel for Mg and is found primarily in the kidneys, distal small intestine, and colon [16]. The epidermal growth factor (EGF) and its receptor (EGFR) regulate the activity of the Mg channel TRPM6. Abnormal activation of EGF causes TRPM6 in the cytoplasm of renal cells to move toward the cell membrane, resulting in increased Mg reabsorption [17,18].

Consequently, EFGR inhibitors could theoretically affect magnesium absorption and induce hypomagnesemia. Consistent with this theory, several studies have reported that the treatment of tumors with EGFR monoclonal antibodies induces hypomagnesemia. Patients treated with cetuximab, alone or in combination with other therapies, have been reported to experience hypomagnesemia [19,20,21]. Anti-EGFR antibodies inhibit TRPM6 activity, reduce Mg influx into cells, and inhibit renal Mg reabsorption. Mutations in the TRPM6 gene, which encodes the epithelial Mg channel, result in secondary hypocalcemia; changes in renal function also affect Mg levels [22,23]. Therefore, after adjusting for liver and kidney function, K, Ca, and other electrolytes in the multiple regression analysis, the outcomes of our study remained relatively unchanged. This further demonstrated the predictive nature of Mg in EGFR-TKI treatment.

So far, no significant clinical trials have demonstrated a clear correlation between EGFR-TKI (gefitinib, erlotinib, or lapatinib) and hypomagnesemia [24,25]. Unlike anti-EGFR monoclonal antibodies, the precise effect of EGFR-TKI on hypomagnesemia remains unclear. Dimke et al. demonstrated that erlotinib can alter EGF-stimulated TRPM6 channel activity at the cellular level. However, animal studies indicate that normal therapeutic doses of erlotinib have no significant effect on serum Mg levels in humans [26].

Mg is a crucial element required to form the active structures of protein kinases, including receptor tyrosine kinases [27]. Cellular studies indicate that high Mg levels can increase tyrosine kinase activity, as both enzyme activity and phosphate transfer require Mg molecules. The Mg-adenosine triphosphate complex binds protein substrates and catalyzes energy for signaling pathway transmission [28,29,30]. Thus, it can be inferred that Mg levels promote EGFR-related pathways. Thus, it can be inferred that Mg levels promote EGFR-related pathways. We hypothesize that patients with elevated serum Mg levels who are treated with EGFR-TKI may have longer PFS and OS based on the following: EGFR mutations lead to increased Mg absorption; that is, elevated Mg levels indicate that EGFR mutations account for a higher proportion of tumor development, thereby increasing the sensitivity of EGFR-TKI treatment. Further research is required to confirm these hypotheses.

Interaction tests demonstrated that gender and smoking factors interacted with Mg levels, while smoking alone interacted with Mg levels both before and after therapy. In a large clinical study of esophageal cancer, the interaction between Mg intake and smoking was statistically significant [31]. However, this study showed a strong positive correlation between Mg and the incidence of esophageal adenocarcinoma among non-smokers than among smokers. In our study, smokers also represented a special group. In patients with prognostic risk factors, such as those over 65 years of age, those with a history of hypertension and other diseases, and those with a low BMI, Mg tended to be a protective factor for OS, although this was not statistically significant.

Chemotherapy utilizing platinum-based agents can impair renal function and result in hypomagnesemia, while anti-EGFR monoclonal antibody therapy can affect Mg absorption. Furthermore, several studies have demonstrated that magnesium supplementation prior to or during treatment enhances patient outcomes [32,33,34]. A study by Minzi et al. revealed that supplementing electrolytes can reduce the risk of nephrotoxicity caused by chemotherapy with cisplatin [32]. Therefore, in combination with our study results, we hypothesize that exogenous electrolyte supplementation during EGFR-TKI therapy may affect therapeutic efficacy, particularly in patients with a history of smoking and other risk factors. However, no studies have reported this previously; therefore, additional clinical trials are required to verify these results.

Our research had several limitations. First, it was a retrospective study with a limited sample size; therefore, bias was inevitable. Second, we did not investigate the effect of electrolyte supplementation on prognosis during therapy. Third, additional follow-up is required to determine the impact of a steady increase in Mg levels on treatment outcomes.

5 Conclusion

Our findings indicate that maintaining a high Mg level is a significant predictor of PFS and OS in patients with NSCLC undergoing EGFR-TKI therapy. Smokers may represent a unique population demonstrating a significant relationship between OS and Mg levels. These results provide new insight into the underlying mechanisms of EGFR-TKI therapy associated with electrolyte balance.


tel: +86 0551 62922807, fax: +86 0551 62922807

Acknowledgments

We would like to acknowledge the hard and dedicated work of all the staff who implemented the intervention and evaluation components of the study.

  1. Funding information: This work was funded by the Colleges and Universities in Anhui Province Natural Science Research Projects (No. KJ2018A0208), the Natural Science Foundation project of Anhui Province (2308085MH237, 1708085MH178), Colleges and Universities Provincial Natural Science Research Project of Anhui (2023AH053315), Research Fund of Anhui Institute of translational medicine (2022zhyx-C22), and the Co-construction Project of Clinical and Preliminary Disciplines of Anhui Medical University (2020lcxk003, 2021lcxk005).

  2. Author contributions: Conception and design of the research: Fang-Zhou Xu, Fu-Rong Meng; acquisition of data: Lu Xu, Fang-Zhou Xu; analysis and interpretation of the data: Wan-Jing Li, Lu Xu; statistical analysis: Hao Zhang, Wan-Jing Li; obtaining financing: Yan-Bei Zhang, Xiao-Yun Fan; writing of the manuscript: Fang-Zhou Xu, Fu-Rong Meng, Hao Zhang; critical revision of the manuscript for intellectual content: Yan-Bei Zhang, Xiao-Yun Fan. All authors read and approved the final draft.

  3. Conflict of interest: Authors state no conflict of interest.

  4. Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–56.Search in Google Scholar

[2] Voruganti T, Soulos PR, Mamtani R, Presley CJ, Gross CP. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol. 2023;9(3):334–41.Search in Google Scholar

[3] Siegel Rebecca L, Miller Kimberly D, Fuchs Hannah E, Jemal A. Cancer statistics, 2021. CA: Cancer J Clin. 2021;71(1):7–33.Search in Google Scholar

[4] Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022;170:41–51.Search in Google Scholar

[5] Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29:i20–7.Search in Google Scholar

[6] Ebrahimi Mousavi S, Ghoreishy SM, Hemmati A, Mohammadi H. Association between magnesium concentrations and prediabetes: a systematic review and meta-analysis. Sci Rep. 2021;11(1):24388.Search in Google Scholar

[7] Lötscher J, Líndez AA, Kirchhammer N, Cribioli E, Attianese GM, Trefny MP, et al. Magnesium sensing via LFA-1 regulates CD8 + T cell effector function. Cell. 2022;185(4):585–602.Search in Google Scholar

[8] Liu W, Qdaisat A, Ferrarotto R, Fuller CD, Guo M, Meyer LA, et al. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer. 2021;127(4):528–34.Search in Google Scholar

[9] Wang L, Chen F, Liu R, Shi L, Zhao G, Yan Z. Gene expression and immune infiltration in melanoma patients with different mutation burden. BMC Cancer. 2021;21(1):379.Search in Google Scholar

[10] Kunutsor SK, Whitehouse MR, Blom AW, Laukkanen JA. Low serum magnesium levels are associated with increased risk of fractures: a long-term prospective cohort study. Eur J Epidemiol. 2017;32(7):593–603.Search in Google Scholar

[11] Hu S, Wang S, Zhang W, Su L, Ye J, Zhang D, et al. Associations between serum total cholesterol level and bone mineral density in older adults. Aging (Albany NY). 2023;15(5):1330–42.Search in Google Scholar

[12] Crintea A, Drugan C, Constantin AM, Lupan I, Fekete Z, Silaghi CN, et al. Assessment of specific tumoral markers, inflammatory status, and vitamin D metabolism before and after the first chemotherapy cycle in patients with lung cancer. Biology (Basel). 2022;11(7):1033.Search in Google Scholar

[13] Jokic V, Savic-Vujovic K, Spasic J, Stanic N, Marinkovic M, Radosavljevic D, et al. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Rev Anticancer Ther. 2021;21(6):673–9.Search in Google Scholar

[14] Yu YC, Paragomi P, Wang R, Liang F, Luu HN, Behari J, et al. High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease. Cancer. 2023;129(15):2341–7.Search in Google Scholar

[15] Azem R, Daou R, Bassil E, Anvari EM, Taliercio JJ, Arrigain S, et al. Serum magnesium, mortality and disease progression in chronic kidney disease. BMC Nephrol. 2020;21(1):49.Search in Google Scholar

[16] de Baaij JH. Magnesium reabsorption in the kidney. Am J Physiol Ren Physiol. 2023;324(3):F227–44.Search in Google Scholar

[17] Ledeganck KJ, Boulet GA, Bogers JJ, Verpooten GA, De Winter BY. The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity. PLoS One. 2013;8(2):e57016.Search in Google Scholar

[18] Marneros AG. Magnesium and calcium homeostasis depend on KCTD1 function in the distal nephron. Cell Rep. 2021;34(2):108616.Search in Google Scholar

[19] Sahashi Y, Nawa T. Incessant atrial tachycardia following combination chemotherapy with cetuximab, cisplatin and 5-fluorouracil for hypopharyngeal cancer. Cardiovasc Toxicol. 2021;21(6):494–7.Search in Google Scholar

[20] Pietropaolo G, Pugliese D, Armuzzi A, Guidi L, Gasbarrini A, Rapaccini GL, et al. Magnesium absorption in intestinal cells: evidence of cross-talk between EGF and TRPM6 and novel implications for cetuximab therapy. Nutrients. 2020;12(11):3277.Search in Google Scholar

[21] Matsukane R, Isshiki R, Suetsugu K, Minami H, Hata K, Matsuo M, et al. Risk factors of cetuximab-induced hypomagnesemia and the effect of magnesium prophylaxis in patients with head and neck cancer: a retrospective study. Biol Pharm Bull. 2024;47(3):732–8.Search in Google Scholar

[22] Yin S, Zhou Z, Lin T, Wang X. Magnesium depletion score is associated with long-term mortality in chronic kidney diseases: a prospective population-based cohort study. J Nephrol. 2023;36(3):755–65.Search in Google Scholar

[23] Franken GA, Adella A, Bindels RJ, de Baaij JH. Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney. Acta Physiol. 2021;231(2):e13528.Search in Google Scholar

[24] Costa A, Tejpar S, Prenen H, Van Cutsem E. Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. Target Oncol. 2011;6(4):227–33.Search in Google Scholar

[25] Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2021;160:103305.Search in Google Scholar

[26] Dimke H, van der Wijst J, Alexander TR, Meijer IM, Mulder GM, van Goor H, et al. Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol. 2010;21(8):1309–16.Search in Google Scholar

[27] Roskoski Jr R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25.Search in Google Scholar

[28] Bastidas AC, Deal MS, Steichen JM, Guo Y, Wu J, Taylor SS. Phosphoryl transfer by protein kinase A is captured in a crystal lattice. J Am Chem Soc. 2013;135(12):4788–98.Search in Google Scholar

[29] Kostov K. Effects of magnesium deficiency on mechanisms of insulin resistance in type 2 diabetes: Focusing on the processes of insulin secretion and signalinging. Int J Mol Sci. 2019;20(6):1351.Search in Google Scholar

[30] Kanellopoulou C, George AB, Masutani E, Cannons JL, Ravell JC, Yamamoto TN, et al. Mg2+ regulation of kinase signaling and immune function. J Exp Med. 2019;216(8):1828–42.Search in Google Scholar

[31] Shah SC, Dai Q, Zhu X, Peek Jr RM, Roumie C, Shrubsole MJ. Associations between calcium and magnesium intake and the risk of incident oesophageal cancer: an analysis of the NIH-AARP Diet and Health Study prospective cohort. Br J Cancer. 2020;122(12):1857–64.Search in Google Scholar

[32] Minzi OM, Lyimo TE, Furia FF, Marealle AI, Kilonzi M, Bwire GM, et al. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol Toxicol. 2020;21(1):69.Search in Google Scholar

[33] Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, et al. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am J Physiol-Renal Physiology. 2015;309(1):F35–47.Search in Google Scholar

[34] Sato J, Ishikawa H, Tanaka R, Sino M. Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab. Cancer Chemotherapy Pharmacol. 2019;83(4):673–9.Search in Google Scholar

Received: 2024-02-25
Revised: 2024-05-29
Accepted: 2024-06-17
Published Online: 2024-07-24

© 2024 the author(s), published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Biomedical Sciences
  2. Constitutive and evoked release of ATP in adult mouse olfactory epithelium
  3. LARP1 knockdown inhibits cultured gastric carcinoma cell cycle progression and metastatic behavior
  4. PEGylated porcine–human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications
  5. Research progress on ocular complications caused by type 2 diabetes mellitus and the function of tears and blepharons
  6. The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway
  7. Brucella infection combined with Nocardia infection: A case report and literature review
  8. Detection of serum interleukin-18 level and neutrophil/lymphocyte ratio in patients with antineutrophil cytoplasmic antibody-associated vasculitis and its clinical significance
  9. Ang-1, Ang-2, and Tie2 are diagnostic biomarkers for Henoch-Schönlein purpura and pediatric-onset systemic lupus erythematous
  10. PTTG1 induces pancreatic cancer cell proliferation and promotes aerobic glycolysis by regulating c-myc
  11. Role of serum B-cell-activating factor and interleukin-17 as biomarkers in the classification of interstitial pneumonia with autoimmune features
  12. Effectiveness and safety of a mumps containing vaccine in preventing laboratory-confirmed mumps cases from 2002 to 2017: A meta-analysis
  13. Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms
  14. A case of Trousseau syndrome: Screening, detection and complication
  15. Application of the integrated airway humidification device enhances the humidification effect of the rabbit tracheotomy model
  16. Preparation of Cu2+/TA/HAP composite coating with anti-bacterial and osteogenic potential on 3D-printed porous Ti alloy scaffolds for orthopedic applications
  17. Aquaporin-8 promotes human dermal fibroblasts to counteract hydrogen peroxide-induced oxidative damage: A novel target for management of skin aging
  18. Current research and evidence gaps on placental development in iron deficiency anemia
  19. Single-nucleotide polymorphism rs2910829 in PDE4D is related to stroke susceptibility in Chinese populations: The results of a meta-analysis
  20. Pheochromocytoma-induced myocardial infarction: A case report
  21. Kaempferol regulates apoptosis and migration of neural stem cells to attenuate cerebral infarction by O‐GlcNAcylation of β-catenin
  22. Sirtuin 5 regulates acute myeloid leukemia cell viability and apoptosis by succinylation modification of glycine decarboxylase
  23. Apigenin 7-glucoside impedes hypoxia-induced malignant phenotypes of cervical cancer cells in a p16-dependent manner
  24. KAT2A changes the function of endometrial stromal cells via regulating the succinylation of ENO1
  25. Current state of research on copper complexes in the treatment of breast cancer
  26. Exploring antioxidant strategies in the pathogenesis of ALS
  27. Helicobacter pylori causes gastric dysbacteriosis in chronic gastritis patients
  28. IL-33/soluble ST2 axis is associated with radiation-induced cardiac injury
  29. The predictive value of serum NLR, SII, and OPNI for lymph node metastasis in breast cancer patients with internal mammary lymph nodes after thoracoscopic surgery
  30. Carrying SNP rs17506395 (T > G) in TP63 gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso
  31. P2X7 receptor: A receptor closely linked with sepsis-associated encephalopathy
  32. Probiotics for inflammatory bowel disease: Is there sufficient evidence?
  33. Identification of KDM4C as a gene conferring drug resistance in multiple myeloma
  34. Microbial perspective on the skin–gut axis and atopic dermatitis
  35. Thymosin α1 combined with XELOX improves immune function and reduces serum tumor markers in colorectal cancer patients after radical surgery
  36. Highly specific vaginal microbiome signature for gynecological cancers
  37. Sample size estimation for AQP4-IgG seropositive optic neuritis: Retinal damage detection by optical coherence tomography
  38. The effects of SDF-1 combined application with VEGF on femoral distraction osteogenesis in rats
  39. Fabrication and characterization of gold nanoparticles using alginate: In vitro and in vivo assessment of its administration effects with swimming exercise on diabetic rats
  40. Mitigating digestive disorders: Action mechanisms of Mediterranean herbal active compounds
  41. Distribution of CYP2D6 and CYP2C19 gene polymorphisms in Han and Uygur populations with breast cancer in Xinjiang, China
  42. VSP-2 attenuates secretion of inflammatory cytokines induced by LPS in BV2 cells by mediating the PPARγ/NF-κB signaling pathway
  43. Factors influencing spontaneous hypothermia after emergency trauma and the construction of a predictive model
  44. Long-term administration of morphine specifically alters the level of protein expression in different brain regions and affects the redox state
  45. Application of metagenomic next-generation sequencing technology in the etiological diagnosis of peritoneal dialysis-associated peritonitis
  46. Clinical diagnosis, prevention, and treatment of neurodyspepsia syndrome using intelligent medicine
  47. Case report: Successful bronchoscopic interventional treatment of endobronchial leiomyomas
  48. Preliminary investigation into the genetic etiology of short stature in children through whole exon sequencing of the core family
  49. Cystic adenomyoma of the uterus: Case report and literature review
  50. Mesoporous silica nanoparticles as a drug delivery mechanism
  51. Dynamic changes in autophagy activity in different degrees of pulmonary fibrosis in mice
  52. Vitamin D deficiency and inflammatory markers in type 2 diabetes: Big data insights
  53. Lactate-induced IGF1R protein lactylation promotes proliferation and metabolic reprogramming of lung cancer cells
  54. Meta-analysis on the efficacy of allogeneic hematopoietic stem cell transplantation to treat malignant lymphoma
  55. Mitochondrial DNA drives neuroinflammation through the cGAS-IFN signaling pathway in the spinal cord of neuropathic pain mice
  56. Application value of artificial intelligence algorithm-based magnetic resonance multi-sequence imaging in staging diagnosis of cervical cancer
  57. Embedded monitoring system and teaching of artificial intelligence online drug component recognition
  58. Investigation into the association of FNDC1 and ADAMTS12 gene expression with plumage coloration in Muscovy ducks
  59. Yak meat content in feed and its impact on the growth of rats
  60. A rare case of Richter transformation with breast involvement: A case report and literature review
  61. First report of Nocardia wallacei infection in an immunocompetent patient in Zhejiang province
  62. Rhodococcus equi and Brucella pulmonary mass in immunocompetent: A case report and literature review
  63. Downregulation of RIP3 ameliorates the left ventricular mechanics and function after myocardial infarction via modulating NF-κB/NLRP3 pathway
  64. Evaluation of the role of some non-enzymatic antioxidants among Iraqi patients with non-alcoholic fatty liver disease
  65. The role of Phafin proteins in cell signaling pathways and diseases
  66. Ten-year anemia as initial manifestation of Castleman disease in the abdominal cavity: A case report
  67. Coexistence of hereditary spherocytosis with SPTB P.Trp1150 gene variant and Gilbert syndrome: A case report and literature review
  68. Utilization of convolutional neural networks to analyze microscopic images for high-throughput screening of mesenchymal stem cells
  69. Exploratory evaluation supported by experimental and modeling approaches of Inula viscosa root extract as a potent corrosion inhibitor for mild steel in a 1 M HCl solution
  70. Imaging manifestations of ductal adenoma of the breast: A case report
  71. Gut microbiota and sleep: Interaction mechanisms and therapeutic prospects
  72. Isomangiferin promotes the migration and osteogenic differentiation of rat bone marrow mesenchymal stem cells
  73. Prognostic value and microenvironmental crosstalk of exosome-related signatures in human epidermal growth factor receptor 2 positive breast cancer
  74. Circular RNAs as potential biomarkers for male severe sepsis
  75. Knockdown of Stanniocalcin-1 inhibits growth and glycolysis in oral squamous cell carcinoma cells
  76. The expression and biological role of complement C1s in esophageal squamous cell carcinoma
  77. A novel GNAS mutation in pseudohypoparathyroidism type 1a with articular flexion deformity: A case report
  78. Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy
  79. HSPB1 alleviates acute-on-chronic liver failure via the P53/Bax pathway
  80. IgG4-related disease complicated by PLA2R-associated membranous nephropathy: A case report
  81. Baculovirus-mediated endostatin and angiostatin activation of autophagy through the AMPK/AKT/mTOR pathway inhibits angiogenesis in hepatocellular carcinoma
  82. Metformin mitigates osteoarthritis progression by modulating the PI3K/AKT/mTOR signaling pathway and enhancing chondrocyte autophagy
  83. Evaluation of the activity of antimicrobial peptides against bacterial vaginosis
  84. Atypical presentation of γ/δ mycosis fungoides with an unusual phenotype and SOCS1 mutation
  85. Analysis of the microecological mechanism of diabetic kidney disease based on the theory of “gut–kidney axis”: A systematic review
  86. Omega-3 fatty acids prevent gestational diabetes mellitus via modulation of lipid metabolism
  87. Refractory hypertension complicated with Turner syndrome: A case report
  88. Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma
  89. Association of low attenuation area scores with pulmonary function and clinical prognosis in patients with chronic obstructive pulmonary disease
  90. Long non-coding RNAs in bone formation: Key regulators and therapeutic prospects
  91. The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein
  92. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential diagnostic markers for rebleeding in patients with esophagogastric variceal bleeding
  93. G protein-coupled receptor 1 participating in the mechanism of mediating gestational diabetes mellitus by phosphorylating the AKT pathway
  94. LL37-mtDNA regulates viability, apoptosis, inflammation, and autophagy in lipopolysaccharide-treated RLE-6TN cells by targeting Hsp90aa1
  95. The analgesic effect of paeoniflorin: A focused review
  96. Chemical composition’s effect on Solanum nigrum Linn.’s antioxidant capacity and erythrocyte protection: Bioactive components and molecular docking analysis
  97. Knockdown of HCK promotes HREC cell viability and inner blood–retinal barrier integrity by regulating the AMPK signaling pathway
  98. The role of rapamycin in the PINK1/Parkin signaling pathway in mitophagy in podocytes
  99. Laryngeal non-Hodgkin lymphoma: Report of four cases and review of the literature
  100. Clinical value of macrogenome next-generation sequencing on infections
  101. Overview of dendritic cells and related pathways in autoimmune uveitis
  102. TAK-242 alleviates diabetic cardiomyopathy via inhibiting pyroptosis and TLR4/CaMKII/NLRP3 pathway
  103. Hypomethylation in promoters of PGC-1α involved in exercise-driven skeletal muscular alterations in old age
  104. Profile and antimicrobial susceptibility patterns of bacteria isolated from effluents of Kolladiba and Debark hospitals
  105. The expression and clinical significance of syncytin-1 in serum exosomes of hepatocellular carcinoma patients
  106. A histomorphometric study to evaluate the therapeutic effects of biosynthesized silver nanoparticles on the kidneys infected with Plasmodium chabaudi
  107. PGRMC1 and PAQR4 are promising molecular targets for a rare subtype of ovarian cancer
  108. Analysis of MDA, SOD, TAOC, MNCV, SNCV, and TSS scores in patients with diabetes peripheral neuropathy
  109. SLIT3 deficiency promotes non-small cell lung cancer progression by modulating UBE2C/WNT signaling
  110. The relationship between TMCO1 and CALR in the pathological characteristics of prostate cancer and its effect on the metastasis of prostate cancer cells
  111. Heterogeneous nuclear ribonucleoprotein K is a potential target for enhancing the chemosensitivity of nasopharyngeal carcinoma
  112. PHB2 alleviates retinal pigment epithelium cell fibrosis by suppressing the AGE–RAGE pathway
  113. Anti-γ-aminobutyric acid-B receptor autoimmune encephalitis with syncope as the initial symptom: Case report and literature review
  114. Comparative analysis of chloroplast genome of Lonicera japonica cv. Damaohua
  115. Human umbilical cord mesenchymal stem cells regulate glutathione metabolism depending on the ERK–Nrf2–HO-1 signal pathway to repair phosphoramide mustard-induced ovarian cancer cells
  116. Electroacupuncture on GB acupoints improves osteoporosis via the estradiol–PI3K–Akt signaling pathway
  117. Renalase protects against podocyte injury by inhibiting oxidative stress and apoptosis in diabetic nephropathy
  118. Review: Dicranostigma leptopodum: A peculiar plant of Papaveraceae
  119. Combination effect of flavonoids attenuates lung cancer cell proliferation by inhibiting the STAT3 and FAK signaling pathway
  120. Renal microangiopathy and immune complex glomerulonephritis induced by anti-tumour agents: A case report
  121. Correlation analysis of AVPR1a and AVPR2 with abnormal water and sodium and potassium metabolism in rats
  122. Gastrointestinal health anti-diarrheal mixture relieves spleen deficiency-induced diarrhea through regulating gut microbiota
  123. Myriad factors and pathways influencing tumor radiotherapy resistance
  124. Exploring the effects of culture conditions on Yapsin (YPS) gene expression in Nakaseomyces glabratus
  125. Screening of prognostic core genes based on cell–cell interaction in the peripheral blood of patients with sepsis
  126. Coagulation factor II thrombin receptor as a promising biomarker in breast cancer management
  127. Ileocecal mucinous carcinoma misdiagnosed as incarcerated hernia: A case report
  128. Methyltransferase like 13 promotes malignant behaviors of bladder cancer cells through targeting PI3K/ATK signaling pathway
  129. The debate between electricity and heat, efficacy and safety of irreversible electroporation and radiofrequency ablation in the treatment of liver cancer: A meta-analysis
  130. ZAG promotes colorectal cancer cell proliferation and epithelial–mesenchymal transition by promoting lipid synthesis
  131. Baicalein inhibits NLRP3 inflammasome activation and mitigates placental inflammation and oxidative stress in gestational diabetes mellitus
  132. Impact of SWCNT-conjugated senna leaf extract on breast cancer cells: A potential apoptotic therapeutic strategy
  133. MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro
  134. Major ozonated autohemotherapy promoted functional recovery following spinal cord injury in adult rats via the inhibition of oxidative stress and inflammation
  135. Axodendritic targeting of TAU and MAP2 and microtubule polarization in iPSC-derived versus SH-SY5Y-derived human neurons
  136. Differential expression of phosphoinositide 3-kinase/protein kinase B and Toll-like receptor/nuclear factor kappa B signaling pathways in experimental obesity Wistar rat model
  137. The therapeutic potential of targeting Oncostatin M and the interleukin-6 family in retinal diseases: A comprehensive review
  138. BA inhibits LPS-stimulated inflammatory response and apoptosis in human middle ear epithelial cells by regulating the Nf-Kb/Iκbα axis
  139. Role of circRMRP and circRPL27 in chronic obstructive pulmonary disease
  140. Investigating the role of hyperexpressed HCN1 in inducing myocardial infarction through activation of the NF-κB signaling pathway
  141. Characterization of phenolic compounds and evaluation of anti-diabetic potential in Cannabis sativa L. seeds: In vivo, in vitro, and in silico studies
  142. Quantitative immunohistochemistry analysis of breast Ki67 based on artificial intelligence
  143. Ecology and Environmental Science
  144. Screening of different growth conditions of Bacillus subtilis isolated from membrane-less microbial fuel cell toward antimicrobial activity profiling
  145. Degradation of a mixture of 13 polycyclic aromatic hydrocarbons by commercial effective microorganisms
  146. Evaluation of the impact of two citrus plants on the variation of Panonychus citri (Acari: Tetranychidae) and beneficial phytoseiid mites
  147. Prediction of present and future distribution areas of Juniperus drupacea Labill and determination of ethnobotany properties in Antalya Province, Türkiye
  148. Population genetics of Todarodes pacificus (Cephalopoda: Ommastrephidae) in the northwest Pacific Ocean via GBS sequencing
  149. A comparative analysis of dendrometric, macromorphological, and micromorphological characteristics of Pistacia atlantica subsp. atlantica and Pistacia terebinthus in the middle Atlas region of Morocco
  150. Macrofungal sporocarp community in the lichen Scots pine forests
  151. Assessing the proximate compositions of indigenous forage species in Yemen’s pastoral rangelands
  152. Food Science
  153. Gut microbiota changes associated with low-carbohydrate diet intervention for obesity
  154. Reexamination of Aspergillus cristatus phylogeny in dark tea: Characteristics of the mitochondrial genome
  155. Differences in the flavonoid composition of the leaves, fruits, and branches of mulberry are distinguished based on a plant metabolomics approach
  156. Investigating the impact of wet rendering (solventless method) on PUFA-rich oil from catfish (Clarias magur) viscera
  157. Non-linear associations between cardiovascular metabolic indices and metabolic-associated fatty liver disease: A cross-sectional study in the US population (2017–2020)
  158. Knockdown of USP7 alleviates atherosclerosis in ApoE-deficient mice by regulating EZH2 expression
  159. Utility of dairy microbiome as a tool for authentication and traceability
  160. Agriculture
  161. Enhancing faba bean (Vicia faba L.) productivity through establishing the area-specific fertilizer rate recommendation in southwest Ethiopia
  162. Impact of novel herbicide based on synthetic auxins and ALS inhibitor on weed control
  163. Perspectives of pteridophytes microbiome for bioremediation in agricultural applications
  164. Fertilizer application parameters for drip-irrigated peanut based on the fertilizer effect function established from a “3414” field trial
  165. Improving the productivity and profitability of maize (Zea mays L.) using optimum blended inorganic fertilization
  166. Application of leaf multispectral analyzer in comparison to hyperspectral device to assess the diversity of spectral reflectance indices in wheat genotypes
  167. Animal Sciences
  168. Knockdown of ANP32E inhibits colorectal cancer cell growth and glycolysis by regulating the AKT/mTOR pathway
  169. Development of a detection chip for major pathogenic drug-resistant genes and drug targets in bovine respiratory system diseases
  170. Exploration of the genetic influence of MYOT and MB genes on the plumage coloration of Muscovy ducks
  171. Transcriptome analysis of adipose tissue in grazing cattle: Identifying key regulators of fat metabolism
  172. Comparison of nutritional value of the wild and cultivated spiny loaches at three growth stages
  173. Transcriptomic analysis of liver immune response in Chinese spiny frog (Quasipaa spinosa) infected with Proteus mirabilis
  174. Disruption of BCAA degradation is a critical characteristic of diabetic cardiomyopathy revealed by integrated transcriptome and metabolome analysis
  175. Plant Sciences
  176. Effect of long-term in-row branch covering on soil microorganisms in pear orchards
  177. Photosynthetic physiological characteristics, growth performance, and element concentrations reveal the calcicole–calcifuge behaviors of three Camellia species
  178. Transcriptome analysis reveals the mechanism of NaHCO3 promoting tobacco leaf maturation
  179. Bioinformatics, expression analysis, and functional verification of allene oxide synthase gene HvnAOS1 and HvnAOS2 in qingke
  180. Water, nitrogen, and phosphorus coupling improves gray jujube fruit quality and yield
  181. Improving grape fruit quality through soil conditioner: Insights from RNA-seq analysis of Cabernet Sauvignon roots
  182. Role of Embinin in the reabsorption of nucleus pulposus in lumbar disc herniation: Promotion of nucleus pulposus neovascularization and apoptosis of nucleus pulposus cells
  183. Revealing the effects of amino acid, organic acid, and phytohormones on the germination of tomato seeds under salinity stress
  184. Combined effects of nitrogen fertilizer and biochar on the growth, yield, and quality of pepper
  185. Comprehensive phytochemical and toxicological analysis of Chenopodium ambrosioides (L.) fractions
  186. Impact of “3414” fertilization on the yield and quality of greenhouse tomatoes
  187. Exploring the coupling mode of water and fertilizer for improving growth, fruit quality, and yield of the pear in the arid region
  188. Metagenomic analysis of endophytic bacteria in seed potato (Solanum tuberosum)
  189. Antibacterial, antifungal, and phytochemical properties of Salsola kali ethanolic extract
  190. Exploring the hepatoprotective properties of citronellol: In vitro and in silico studies on ethanol-induced damage in HepG2 cells
  191. Enhanced osmotic dehydration of watermelon rind using honey–sucrose solutions: A study on pre-treatment efficacy and mass transfer kinetics
  192. Effects of exogenous 2,4-epibrassinolide on photosynthetic traits of 53 cowpea varieties under NaCl stress
  193. Comparative transcriptome analysis of maize (Zea mays L.) seedlings in response to copper stress
  194. An optimization method for measuring the stomata in cassava (Manihot esculenta Crantz) under multiple abiotic stresses
  195. Fosinopril inhibits Ang II-induced VSMC proliferation, phenotype transformation, migration, and oxidative stress through the TGF-β1/Smad signaling pathway
  196. Antioxidant and antimicrobial activities of Salsola imbricata methanolic extract and its phytochemical characterization
  197. Bioengineering and Biotechnology
  198. Absorbable calcium and phosphorus bioactive membranes promote bone marrow mesenchymal stem cells osteogenic differentiation for bone regeneration
  199. New advances in protein engineering for industrial applications: Key takeaways
  200. An overview of the production and use of Bacillus thuringiensis toxin
  201. Research progress of nanoparticles in diagnosis and treatment of hepatocellular carcinoma
  202. Bioelectrochemical biosensors for water quality assessment and wastewater monitoring
  203. PEI/MMNs@LNA-542 nanoparticles alleviate ICU-acquired weakness through targeted autophagy inhibition and mitochondrial protection
  204. Unleashing of cytotoxic effects of thymoquinone-bovine serum albumin nanoparticles on A549 lung cancer cells
  205. Erratum
  206. Erratum to “Investigating the association between dietary patterns and glycemic control among children and adolescents with T1DM”
  207. Erratum to “Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation”
  208. Retraction
  209. Retraction to “MiR-223-3p regulates cell viability, migration, invasion, and apoptosis of non-small cell lung cancer cells by targeting RHOB”
  210. Retraction to “A data mining technique for detecting malignant mesothelioma cancer using multiple regression analysis”
  211. Special Issue on Advances in Neurodegenerative Disease Research and Treatment
  212. Transplantation of human neural stem cell prevents symptomatic motor behavior disability in a rat model of Parkinson’s disease
  213. Special Issue on Multi-omics
  214. Inflammasome complex genes with clinical relevance suggest potential as therapeutic targets for anti-tumor drugs in clear cell renal cell carcinoma
  215. Gastroesophageal varices in primary biliary cholangitis with anti-centromere antibody positivity: Early onset?
Downloaded on 23.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/biol-2022-0923/html?lang=en
Scroll to top button